Tryton Medical, a developer of stents designed to treat bifurcation lesions, has introduced Tryton Stent System in Switzerland, Sweden, Finland, Turkey, Hungary, Czech Republic, Slovakia and Latvia.
Tryton Medical claimed that its Side Branch Stent System has shown good six-month clinical and angiographic results in a first-in-man study of the system and positive six-month clinical results with a rate of target lesion revascularisation of less than 4%.
The Tryton Side Branch Stent System is used for treating atherosclerotic lesions in the side branch at the site of a bifurcation.
Tryton’s deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system after which a conventional drug-eluting stent is placed in the main vessel.
Tryton Medical’s stent system has received CE mark approval in Europe and is commercially available in 21 countries throughout Europe and the Middle East but is not approved in the US.
Tryton Medical president and CEO Greg Davis said that they were pleased to expand availability of the Tryton Stent System to additional countries in Europe and Eastern Europe.